Century Therapeutics released FY2024 Q3 earnings on November 5 (EST), actual revenue USD 791K (forecast USD 550K), actual EPS USD -0.3699 (forecast USD -0.45)
Brief Summary
Century Therapeutics reported Q3 2024 revenue of $791,000, exceeding the expected $550,000, and an EPS of -$0.3699, which was better than the anticipated -$0.45.
Impact of The News
Century Therapeutics’ Q3 2024 earnings report showed that the company exceeded market expectations in terms of revenue and EPS. Specifically, the revenue was $791,000 compared to the expected $550,000, and the EPS was -$0.3699 versus the anticipated -$0.45.
Financial Performance Comparison:
- Revenue: The company’s revenue performance was better compared to its peers like Micron (MU.O) which reported $8.71 billion in revenue for Q1 2025 , Broadcom (AVGO.O) which had $14.05 billion in Q4 2024 , and Nvidia which reported $35.08 billion in Q3 2025 .
- EPS: Century Therapeutics’ EPS was negative but better than the expected loss, while other companies like Nvidia had a positive adjusted EPS of $0.81 in the same period .
Business Impact and Future Outlook:
- The better-than-expected financial performance may boost investor confidence in Century Therapeutics, potentially leading to a positive impact on stock price and market perception.
- However, the company still operates at a loss, indicating challenges in achieving profitability. The negative EPS suggests ongoing financial struggles that need to be addressed for long-term sustainability.
- The revenue growth indicates some positive momentum in business operations, which could be a sign of potential recovery or growth in the upcoming quarters.
Overall, while Century Therapeutics has shown improvement in key financial metrics, it still faces significant hurdles in terms of profitability and sustained revenue growth. The future business development will likely depend on the company’s ability to continue exceeding market expectations and addressing its financial deficits.
